{
 "@context": "https://clearank.com/llms.txt",
 "@type": "clearank:AssetAnalysis",
 "url": "https://clearank.com/stock/boston-scientific-bsx/",
 "dataUrl": "https://clearank.com/stock/boston-scientific-bsx/data.json",
 "title": "Boston Scientific (BSX) Stock Forecast & Price Target (2026)",
 "description": "Boston Scientific Corp. (BSX) stock: Healthcare, Medical Devices. $63.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
 "headline": "Boston Scientific Corp. (BSX)",
 "published": "2026-07-03T09:18:06+00:00",
 "modified": "2026-09-16T05:21:39.077+00:00",
 "generated": "2026-09-16T11:57:25.856Z",
 "language": "en-US",
 "publisher": {
  "name": "CleaRank",
  "url": "https://clearank.com/"
 },
 "disclaimer": "Educational and informational only; not financial advice. AI-generated analysis reviewed by the CleaRank editorial team; prices delayed up to 15 minutes.",
 "asset": {
  "ticker": "BSX",
  "name": "Boston Scientific Corp.",
  "type": "Common Stock",
  "exchange": "NYSE",
  "currency": "USD",
  "sector": "Healthcare",
  "industry": "Medical Devices",
  "country": "United States",
  "website": "https://www.bostonscientific.com"
 },
 "quote": {
  "price": 43.87,
  "previousClose": 45.05,
  "change": -1.18,
  "changePercent": -2.62,
  "open": 44.32,
  "high": 44.99,
  "low": 43.68,
  "volume": 16014500,
  "averageVolume": 19746040,
  "marketCap": 63577699305,
  "fiftyTwoWeekHigh": 109.5,
  "fiftyTwoWeekLow": 42.2,
  "marketOpen": false,
  "asOf": "2026-09-16T05:21:39.000Z"
 },
 "statistics": {
  "pe": 18.10324,
  "eps": 2.47,
  "dividendYield": 0,
  "beta": 0.568,
  "priceToSales": 3.0864117,
  "priceToBook": 2.5948815,
  "revenueTtm": 20995999744,
  "grossMargin": 0.707092980521867,
  "returnOnEquity": 0.15338999
 },
 "technicals": {
  "rsi": 30.89,
  "macd": -1.16,
  "sma50": 46.92,
  "sma200": 65.14,
  "rsiSignal": "Bearish",
  "trend": "Bearish",
  "pricePosition": "Bearish",
  "macdSignal": "Bearish",
  "rating": "Bearish"
 },
 "analysis": {
  "rating": "Sell",
  "score": 21,
  "consensus": "Sell",
  "fairValue": 43.87,
  "analystTarget": 60,
  "analystCount": 31,
  "wallStreetConsensus": "Buy",
  "generatedAt": "2026-09-16T05:21:39.000Z",
  "priceAtAnalysis": 43.87,
  "volatility": {
   "daily": 2.64,
   "risk": "standard"
  }
 },
 "tradePlan": {
  "bias": "Bearish",
  "conservativeEntry": 44.75,
  "aggressiveEntry": 43.87,
  "stopLoss": 46.76,
  "stopLossPercent": 4.5,
  "targets": [
   42.51,
   40.27,
   38.04
  ]
 },
 "projections": {
  "basis": "Monte Carlo simulation on historical return distribution, re-run daily; not price targets",
  "years": [
   {
    "year": 2027,
    "downside10th": 32.71,
    "base": 46.85,
    "upside90th": 67.1
   },
   {
    "year": 2028,
    "downside10th": 30.11,
    "base": 50.03,
    "upside90th": 83.15
   },
   {
    "year": 2029,
    "downside10th": 28.68,
    "base": 53.43,
    "upside90th": 99.54
   },
   {
    "year": 2030,
    "downside10th": 27.82,
    "base": 57.06,
    "upside90th": 117.04
   },
   {
    "year": 2031,
    "downside10th": 27.3,
    "base": 60.94,
    "upside90th": 136.05
   },
   {
    "year": 2032,
    "downside10th": 27,
    "base": 65.08,
    "upside90th": 156.87
   },
   {
    "year": 2033,
    "downside10th": 26.87,
    "base": 69.5,
    "upside90th": 179.77
   },
   {
    "year": 2034,
    "downside10th": 26.88,
    "base": 74.23,
    "upside90th": 205
   },
   {
    "year": 2035,
    "downside10th": 26.99,
    "base": 79.27,
    "upside90th": 232.84
   },
   {
    "year": 2036,
    "downside10th": 27.19,
    "base": 84.66,
    "upside90th": 263.59
   }
  ]
 },
 "faqCount": 7,
 "sources": [
  "TwelveData",
  "Wall Street consensus"
 ],
 "sections": [
  {
   "id": "price",
   "title": "BSX Price Analysis"
  },
  {
   "id": "market-metrics",
   "title": "Market Metrics",
   "facts": {
    "Open": "$44.32",
    "Day Range": "$43.68 to $44.99",
    "Prev Close": "$45.05",
    "Volume": "16.01M",
    "52-Week Range": "$42.20 to $109.50",
    "Market Cap": "$63.58B"
   }
  },
  {
   "id": "peer-benchmarking",
   "title": "Peer Benchmarking",
   "text": [
    "Sector Position Analysis Trading at a notable discount to sector peers (-43%), which may indicate undervaluation or specific company headwinds."
   ]
  },
  {
   "id": "financials",
   "title": "BSX Financial Performance",
   "text": [
    "Analysis: In the last 5 quarters, BSX beat estimates 4 times. However, the stock fell 2 times the next day. This suggests positive news is often \"priced in\" or investors are selling the news."
   ]
  },
  {
   "id": "analysis",
   "title": "BSX Analysis",
   "text": [
    "Boston Scientific Corp. (BSX) is trading below its 50-day and 200-day moving averages ($46.92 and $65.14), indicating a bearish trend. The 50-day SMA is at $46.92 and the 200-day SMA is at $65.14, with the current price of $43.87 falling below both. The Relative Strength Index (RSI) is at 30.89, classified as 'BEARISH', suggesting weakening momentum. The MACD is also negative at -1.16, reinforcing the bearish technical picture. Volume has been below average recently, with the latest volume at 16.01 million compared to an average of 19.75 million. Key support levels are being tested, and the current price action suggests further downside potential if these levels break. The bearish RSI and MACD, coupled with the price being below critical moving averages, point towards continued weakness in the near term. Investors should monitor volume for any signs of capitulation or renewed buying interest, but the current technical setup is unfavorable.",
    "Insiders have sold over $107.9 million worth of BSX stock versus only $10 million in purchases, indicating a strong heavy insider selling and potentially signaling management's lack of confidence in near-term prospects.",
    "The stock is trading below its 50-day and 200-day moving averages ($46.92 and $65.14), with a bearish RSI (30.89), suggesting continued downside potential.",
    "Boston Scientific has a track record of beating EPS estimates, most recently by 3.61% for the quarter ending June 2026, which could provide underlying support if sustained.",
    "The median analyst price target of $60.00 implies a 36.8% upside from the current price, suggesting Wall Street sees potential for recovery and growth.",
    "The base case for Boston Scientific Corp. (BSX) over the next 6-12 months appears challenging, given the strong bearish signals from insider activity and technical indicators. While analysts have a median price target of $60.00, implying significant upside, the current price action and heavy insider selling suggest these targets may be difficult to achieve in the near term. The stock's position below key moving averages and a bearish RSI indicate potential for further declines. Factors that could alter this outlook include a significant shift in insider sentiment, a strong earnings beat with positive forward guidance, or a successful new product launch that revitalizes growth. Conversely, continued insider selling, a failure to meet earnings expectations, or increased competitive pressure could exacerbate the bearish trend and push the stock towards its lower support levels or even the downside projection of $27.82 from the long-range forecast."
   ],
   "lists": {
    "ProTips": [
     "Monitor insider transactions closely; the current heavy selling trend is a significant bearish signal that warrants caution.",
     "Given the bearish technicals, consider waiting for a confirmed break above the 50-day SMA ($46.92) before considering new long positions.",
     "The divergence between Wall Street's optimistic price targets and insider selling presents a key risk; ensure any investment aligns with your risk tolerance."
    ]
   },
   "catalysts": [
    {
     "type": "Bearish",
     "title": "Heavy Insider Selling Pressure",
     "text": "Insiders have sold over $107.9 million worth of BSX stock versus only $10 million in purchases, indicating a strong heavy insider selling and potentially signaling management's lack of confidence in near-term prospects.",
     "source": "Insider Transactions"
    },
    {
     "type": "Bearish",
     "title": "Bearish Technical Momentum",
     "text": "The stock is trading below its 50-day and 200-day moving averages ($46.92 and $65.14), with a bearish RSI (30.89), suggesting continued downside potential.",
     "source": "Technical Analysis"
    },
    {
     "type": "Bullish",
     "title": "Consistent Earnings Beats",
     "text": "Boston Scientific has a track record of beating EPS estimates, most recently by 3.61% for the quarter ending June 2026, which could provide underlying support if sustained.",
     "source": "Earnings Reports"
    },
    {
     "type": "Bullish",
     "title": "Positive Analyst Price Targets",
     "text": "The median analyst price target of $60.00 implies a 36.8% upside from the current price, suggesting Wall Street sees potential for recovery and growth.",
     "source": "Wall Street Analysts"
    }
   ]
  },
  {
   "id": "key-statistics",
   "title": "Key Statistics",
   "text": [
    "Boston Scientific Corp. (BSX) exhibits a mixed fundamental picture, with a Price-to-Earnings (P/E) ratio of 18.10 and a Price-to-Sales (P/S) ratio of 3.09. These valuations appear reasonable when compared to sector averages, where the median P/E is 31.9 and P/S is 3.7. The company's return on equity stands at a healthy 15.34%, and its profit margin is 17.50%, both exceeding sector medians. The debt-to-equity ratio of 0.50 is also in line with the sector average. However, the company's growth trajectory is moderating, with revenue growth reported at 7.5% and forward estimates for next year's revenue growth at 5.00%. While profitability metrics are strong, the current valuation does not appear significantly undervalued given the slowing growth and substantial insider selling. The company's ability to maintain its growth and profitability in a competitive medical device market will be key to future performance.",
    "Boston Scientific Corp. (BSX) most recently reported earnings for the quarter ending June 2026, with an actual EPS of $0.86, beating the estimate of $0.83 by 3.61%. This earnings beat was accompanied by a slight price decrease of -0.09%. Prior quarters have also shown consistent EPS beats, though the price reaction has varied, including a -1.41% drop following the September 2025 quarter's beat. The company's earnings performance has been solid, consistently meeting or exceeding analyst expectations.",
    "The primary risk for Boston Scientific Corp. (BSX) stems from significant insider selling, with over $107.9 million in sales against $10 million in purchases, indicating a heavy insider selling. This heavy selling pressure from management and key personnel suggests a lack of confidence in near-term prospects, despite positive analyst ratings. Additionally, the stock is trading below its key 50-day and 200-day moving averages, with a bearish RSI, indicating a weak technical outlook that could lead to further price declines. Competition within the medical device sector also presents an ongoing challenge."
   ],
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "Market Cap",
       "cells": [
        "63.58B"
       ]
      },
      {
       "label": "P/E Ratio",
       "cells": [
        "18.10"
       ]
      },
      {
       "label": "EPS (TTM)",
       "cells": [
        "2.47"
       ]
      },
      {
       "label": "Dividend Yield",
       "cells": [
        "0.00%"
       ]
      },
      {
       "label": "52 Week High",
       "cells": [
        "109.50"
       ]
      },
      {
       "label": "52 Week Low",
       "cells": [
        "42.20"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "technical-indicators",
   "title": "Technical Indicators",
   "text": [
    "Technical Rating Bearish RSI Bearish SMA Cross Bearish Price vs SMA Bearish MACD Bearish Moving averages show a lagging Death Cross (50-day: $46.92, 200-day: $65.14), price is trading below the 50-day SMA."
   ],
   "facts": {
    "RSI": "Bearish",
    "SMA Cross": "Bearish",
    "Price vs SMA": "Bearish",
    "MACD": "Bearish"
   },
   "tables": [
    {
     "caption": "",
     "columns": [],
     "rows": [
      {
       "label": "RSI (14)",
       "cells": [
        "30.89"
       ]
      },
      {
       "label": "MACD",
       "cells": [
        "-1.16"
       ]
      },
      {
       "label": "SMA 50",
       "cells": [
        "46.92"
       ]
      },
      {
       "label": "SMA 200",
       "cells": [
        "65.14"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "correlations",
   "title": "Market Correlations",
   "text": [
    "How this stock moves relative to other assets",
    "Based on 1 year of daily price data. Correlations may vary over different time periods."
   ],
   "facts": {
    "Correlation with S&P 500 (SPY)": "+0.29",
    "Correlation with Nasdaq 100 (QQQ)": "+0.23",
    "Correlation with Bitcoin (BTC)": "+0.08",
    "Correlation with Gold (XAU)": "+0.04"
   }
  },
  {
   "id": "trade-plans",
   "title": "BSX Trade Plans",
   "text": [
    "Specific entry, exit, and risk management levels",
    "Lower risk, wait for rally",
    "Higher risk, chasing the move",
    "Volatility-Adjusted Stop Loss Calculated based on RSI (30.9) and current market volatility",
    "Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3"
   ],
   "facts": {
    "TARGET 1": "$42.51",
    "TARGET 2": "$40.27",
    "TARGET 3": "$38.04",
    "STOP LOSS": "$46.76"
   }
  },
  {
   "id": "seasonality",
   "title": "Seasonal Patterns",
   "text": [
    "Historical monthly performance trends",
    "Based on 3 years of historical monthly returns"
   ],
   "facts": {
    "Average Jan return": "+4.68%",
    "Average Feb return": "-1.04%",
    "Average Mar return": "-2.89%",
    "Average Apr return": "+4.45%",
    "Average May return": "+0.23%",
    "Average Jun return": "+0.52%",
    "Average Jul return": "+2.24%",
    "Average Aug return": "+3.13%",
    "Average Sep return": "-1.66%",
    "Average Oct return": "-1.69%",
    "Average Nov return": "+0.50%",
    "Average Dec return": "+1.48%"
   }
  },
  {
   "id": "risk",
   "title": "Risk & Volatility",
   "facts": {
    "Daily Volatility": "2.64%"
   },
   "lists": {
    "Risk considerations": [
     "Monitor position sizing based on current volatility levels",
     "Consider stop-loss placement beyond recent price range",
     "Diversification helps mitigate single-stock risk exposure"
    ]
   }
  },
  {
   "id": "growth",
   "title": "Growth of $10,000",
   "text": [
    "A $10,000 investment in BSX in September 2016 would be worth about $18,668 today, compared with about $35,497 for the same investment in the S&P 500 benchmark."
   ]
  },
  {
   "id": "monte-carlo",
   "title": "Monte Carlo Projection (10yr)",
   "text": [
    "CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in BSX today could grow to about $19,297 by 2036 in the base case, with a bull case near $60,084 and a bear case around $6,198. Projections are statistical simulations, not guarantees."
   ]
  },
  {
   "id": "price-prediction",
   "title": "BSX Stock Price Prediction: 2030",
   "text": [
    "CleaRank's simulation projects a price near $57.06 for BSX by 2030 in the base case, from $43.87 today (1.3x over 4 years). The downside path ends near $27.82. These are outcomes of a Monte Carlo simulation run on BSX's historical return distribution, not price targets, and they assume no dividends are reinvested.",
    "Method: 10,000 simulated price paths using BSX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice."
   ],
   "tables": [
    {
     "caption": "BSX simulated price paths by year",
     "columns": [
      "Year",
      "Downside (10th pct)",
      "Base case",
      "Upside (90th pct)"
     ],
     "rows": [
      {
       "label": "2027",
       "cells": [
        "$32.71",
        "$46.85",
        "$67.10"
       ]
      },
      {
       "label": "2028",
       "cells": [
        "$30.11",
        "$50.03",
        "$83.15"
       ]
      },
      {
       "label": "2029",
       "cells": [
        "$28.68",
        "$53.43",
        "$99.54"
       ]
      },
      {
       "label": "2030",
       "cells": [
        "$27.82",
        "$57.06",
        "$117"
       ]
      },
      {
       "label": "2031",
       "cells": [
        "$27.30",
        "$60.94",
        "$136"
       ]
      },
      {
       "label": "2032",
       "cells": [
        "$27.00",
        "$65.08",
        "$157"
       ]
      },
      {
       "label": "2033",
       "cells": [
        "$26.87",
        "$69.50",
        "$180"
       ]
      },
      {
       "label": "2034",
       "cells": [
        "$26.88",
        "$74.23",
        "$205"
       ]
      },
      {
       "label": "2035",
       "cells": [
        "$26.99",
        "$79.27",
        "$233"
       ]
      },
      {
       "label": "2036",
       "cells": [
        "$27.19",
        "$84.66",
        "$264"
       ]
      }
     ]
    }
   ]
  },
  {
   "id": "people-also-watch",
   "title": "People Also Watch",
   "links": [
    {
     "text": "NTRA Natera, Inc. NASDAQ $350.78 +2.63%",
     "url": "https://clearank.com/stock/natera-ntra/"
    },
    {
     "text": "IDXX IDEXX Laboratories, Inc. NASDAQ $510.73 +0.23%",
     "url": "https://clearank.com/stock/idxx-stock-analysis/"
    },
    {
     "text": "REPL Replimune Group, Inc. NASDAQ $13.03 -0.61%",
     "url": "https://clearank.com/stock/repl-stock-analysis/"
    },
    {
     "text": "REGN Regeneron Pharmaceuticals, Inc. NASDAQ $777.60 -2.03%",
     "url": "https://clearank.com/stock/regeneron-regn/"
    },
    {
     "text": "NVO Novo Nordisk A/S Sponsored NYSE $42.53 -2.12%",
     "url": "https://clearank.com/stock/novo-nordisk-nvo/"
    },
    {
     "text": "VEEV Veeva Systems Inc. NYSE $266.62 +0.36%",
     "url": "https://clearank.com/stock/veev-stock-analysis/"
    },
    {
     "text": "OFIX Orthofix Medical Inc. NASDAQ $9.09 -0.22%",
     "url": "https://clearank.com/stock/ofix-stock-analysis/"
    },
    {
     "text": "EW Edwards Lifesciences Corporation NYSE $85.74 +0.26%",
     "url": "https://clearank.com/stock/ew-stock-analysis/"
    }
   ]
  },
  {
   "id": "related-comparisons",
   "title": "Compare BSX",
   "links": [
    {
     "text": "BSX vs MDT Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/bsx-vs-mdt/"
    },
    {
     "text": "BTC vs ETH Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/btc-vs-eth/"
    },
    {
     "text": "MKTX vs TW Comparison Head-to-head analysis →",
     "url": "https://clearank.com/compare/mktx-vs-tw/"
    }
   ]
  },
  {
   "id": "insider-trading",
   "title": "BSX Insider Trading Analysis",
   "facts": {
    "Bought": "$10.0M",
    "Sold": "$107.9M",
    "Insiders": "19",
    "Avg Transaction": "$3.9M"
   },
   "tables": [
    {
     "caption": "Recent insider transactions in BSX",
     "columns": [
      "Date",
      "Insider",
      "Type",
      "Shares",
      "Value"
     ],
     "rows": [
      {
       "label": "Jun 2, 2025",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "164.4K",
        "$17.1M"
       ]
      },
      {
       "label": "May 1, 2025",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "164.4K",
        "$16.9M"
       ]
      },
      {
       "label": "Apr 1, 2025",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "164.4K",
        "$16.4M"
       ]
      },
      {
       "label": "Feb 2, 2026",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "160.9K",
        "$15.0M"
       ]
      },
      {
       "label": "Nov 5, 2024",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "162.8K",
        "$13.8M"
       ]
      },
      {
       "label": "Oct 7, 2024",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "162.8K",
        "$13.8M"
       ]
      },
      {
       "label": "Sep 5, 2024",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "162.8K",
        "$13.2M"
       ]
      },
      {
       "label": "Oct 7, 2024",
       "cells": [
        "FITZGERALD JOSEPH MICHAEL Officer",
        "Sell",
        "132.5K",
        "$11.3M"
       ]
      },
      {
       "label": "Aug 2, 2021",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "201.0K",
        "$9.2M"
       ]
      },
      {
       "label": "Nov 3, 2020",
       "cells": [
        "MAHONEY MICHAEL F Chief Executive Officer",
        "Sell",
        "259.2K",
        "$9.1M"
       ]
      }
     ]
    }
   ],
   "links": [
    {
     "text": "SEC Form 4",
     "url": "https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&company=Boston+Scientific+Corp.&type=4&dateb=&owner=include&count=40&search_text=&action=getcompany"
    }
   ]
  },
  {
   "id": "faq",
   "title": "Frequently Asked Questions"
  }
 ],
 "faq": [
  {
   "question": "Is Boston Scientific Corp. stock a buy right now?",
   "answer": "Boston Scientific Corp. (BSX) is currently rated 'Sell' by our AI analysis due to heavy insider selling and bearish technicals, despite a 'Buy' consensus from Wall Street analysts. The current price is $43.87, with a median analyst target of $60.00."
  },
  {
   "question": "What is Boston Scientific's stock price forecast for 2030?",
   "answer": "Based on Monte Carlo simulations, Boston Scientific Corp. (BSX) has a base case forecast of $57.06 for 2030, with a downside projection of $27.82 and an upside projection of $117.04. These are statistical outcomes, not guarantees."
  },
  {
   "question": "What are the main risks facing Boston Scientific Corp.?",
   "answer": "The primary risks include significant insider selling totaling over $107.9 million, a bearish technical outlook with the stock below key moving averages, and intense competition within the medical device industry."
  },
  {
   "question": "How does Boston Scientific's valuation compare to its peers?",
   "answer": "Boston Scientific's P/E ratio of 18.10 and P/S ratio of 3.09 are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially more attractive valuation on these metrics. Its profit margin of 17.50% also surpasses the sector median of 6.9%."
  },
  {
   "question": "What was Boston Scientific's most recent earnings performance?",
   "answer": "In the quarter ending June 2026, Boston Scientific reported an EPS of $0.86, beating estimates by 3.61%. The stock price saw a slight decrease of -0.09% following this announcement."
  },
  {
   "question": "What is the Wall Street consensus on Boston Scientific stock?",
   "answer": "Wall Street analysts maintain a 'Buy' consensus for Boston Scientific (BSX), with 31 analysts covering the stock. There are 8 'Strong Buy' ratings, 18 'Buy' ratings, and 5 'Hold' ratings, contributing to a Wall Street score of 77 out of 100."
  },
  {
   "question": "Are there any significant insider transactions for BSX?",
   "answer": "Yes, recent insider activity for BSX indicates a heavy insider selling, with total sales amounting to $107.9 million compared to total purchases of $10 million in recent filings."
  }
 ],
 "related": {
  "peopleAlsoWatch": [
   {
    "ticker": "NTRA",
    "name": "Natera, Inc. NASDAQ",
    "price": "$350.78",
    "change": "+2.63%",
    "url": "https://clearank.com/stock/natera-ntra/"
   },
   {
    "ticker": "IDXX",
    "name": "IDEXX Laboratories, Inc. NASDAQ",
    "price": "$510.73",
    "change": "+0.23%",
    "url": "https://clearank.com/stock/idxx-stock-analysis/"
   },
   {
    "ticker": "REPL",
    "name": "Replimune Group, Inc. NASDAQ",
    "price": "$13.03",
    "change": "-0.61%",
    "url": "https://clearank.com/stock/repl-stock-analysis/"
   },
   {
    "ticker": "REGN",
    "name": "Regeneron Pharmaceuticals, Inc. NASDAQ",
    "price": "$777.60",
    "change": "-2.03%",
    "url": "https://clearank.com/stock/regeneron-regn/"
   },
   {
    "ticker": "NVO",
    "name": "Novo Nordisk A/S Sponsored NYSE",
    "price": "$42.53",
    "change": "-2.12%",
    "url": "https://clearank.com/stock/novo-nordisk-nvo/"
   },
   {
    "ticker": "VEEV",
    "name": "Veeva Systems Inc. NYSE",
    "price": "$266.62",
    "change": "+0.36%",
    "url": "https://clearank.com/stock/veev-stock-analysis/"
   },
   {
    "ticker": "OFIX",
    "name": "Orthofix Medical Inc. NASDAQ",
    "price": "$9.09",
    "change": "-0.22%",
    "url": "https://clearank.com/stock/ofix-stock-analysis/"
   },
   {
    "ticker": "EW",
    "name": "Edwards Lifesciences Corporation NYSE",
    "price": "$85.74",
    "change": "+0.26%",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   }
  ],
  "comparisons": [
   {
    "ticker": "BSX vs MDT Comparison",
    "name": "",
    "url": "https://clearank.com/compare/bsx-vs-mdt/"
   },
   {
    "ticker": "BTC vs ETH Comparison",
    "name": "",
    "url": "https://clearank.com/compare/btc-vs-eth/"
   },
   {
    "ticker": "MKTX vs TW Comparison",
    "name": "",
    "url": "https://clearank.com/compare/mktx-vs-tw/"
   }
  ],
  "sectorHub": {
   "text": "Browse all Healthcare →",
   "url": "https://clearank.com/sector/healthcare/"
  },
  "Newly Tracked": [
   {
    "ticker": "ILMN",
    "text": "Illumina Inc.",
    "url": "https://clearank.com/stock/ilmn-stock-analysis/"
   },
   {
    "ticker": "SPG",
    "text": "Simon Property Group Inc.",
    "url": "https://clearank.com/stock/spg-stock-analysis/"
   },
   {
    "ticker": "JCI",
    "text": "Johnson Controls International",
    "url": "https://clearank.com/stock/jci-stock-analysis/"
   },
   {
    "ticker": "BLDR",
    "text": "Builders FirstSource Inc.",
    "url": "https://clearank.com/stock/bldr-stock-analysis/"
   },
   {
    "ticker": "EIS",
    "text": "iShares MSCI Israel ETF",
    "url": "https://clearank.com/etf/eis-etf-analysis/"
   }
  ],
  "Top Movers (24h)": [
   {
    "ticker": "SBET",
    "text": "↓ 8.96%",
    "url": "https://clearank.com/stock/sharplink-sbet/"
   },
   {
    "ticker": "CAVA",
    "text": "↓ 8.93%",
    "url": "https://clearank.com/stock/cava-group-cava/"
   },
   {
    "ticker": "ARB/USD",
    "text": "↑ 19.42%",
    "url": "https://clearank.com/crypto/arbitrum-arb-usd/"
   },
   {
    "ticker": "INJ/USD",
    "text": "↓ 11.80%",
    "url": "https://clearank.com/crypto/injective-inj/"
   },
   {
    "ticker": "CRV/USD",
    "text": "↓ 11.53%",
    "url": "https://clearank.com/crypto/crv-usd-crypto-analysis/"
   }
  ],
  "Also in Healthcare": [
   {
    "ticker": "ABT",
    "text": "Abbott Laboratories",
    "url": "https://clearank.com/stock/abbott-laboratories-abt/"
   },
   {
    "ticker": "DXCM",
    "text": "DexCom",
    "url": "https://clearank.com/stock/dxcm-stock-analysis/"
   },
   {
    "ticker": "EW",
    "text": "Edwards Lifesciences Corporation",
    "url": "https://clearank.com/stock/ew-stock-analysis/"
   },
   {
    "ticker": "GEHC",
    "text": "GE HealthCare",
    "url": "https://clearank.com/stock/ge-healthcare-gehc/"
   },
   {
    "ticker": "MDT",
    "text": "Medtronic plc",
    "url": "https://clearank.com/stock/medtronic-mdt/"
   }
  ]
 },
 "schema": [
  {
   "@context": "https://schema.org",
   "@graph": [
    {
     "@type": "Place",
     "@id": "https://clearank.com/#place",
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     }
    },
    {
     "@type": "Organization",
     "@id": "https://clearank.com/#organization",
     "name": "CleaRank",
     "alternateName": "CleaRank Financial AI",
     "url": "https://clearank.com",
     "description": "CleaRank is where retail traders research a trade and practice it before risking money. Its research arm, CleaRank Financial AI, publishes daily analysis, trade plans and 10-year projections for more than 1,000 stocks, ETFs, cryptocurrencies, forex pairs and commodities; each page is built from licensed market data, carries the date it was last updated and is reviewed under CleaRank's published editorial code. The CLEAR™ Score rates online brokers and prop firms on regulation, fees, platform reliability and verified trader experience. The research is free; CleaRank is paid for by subscriptions to its trading workbench (Pro $29 a month, Ultra $59 a month), which combines a live trading simulator, a trade journal that imports from broker history, an AI coach grounded in the trader's own trades, a portfolio generator, visualizer and backtester, a prop-firm challenge auditor and 22 trading calculators and scanners. Some free content contains partner links, which are disclosed and do not affect ratings.",
     "slogan": "Clear data. Honest analysis.",
     "logo": {
      "@type": "ImageObject",
      "@id": "https://clearank.com/#logo",
      "url": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "contentUrl": "https://clearank.com/media/uploads/2025/02/CleaRank-Logo-e1738621466340.jpg",
      "caption": "CleaRank",
      "inLanguage": "en-US",
      "width": "336",
      "height": "153"
     },
     "image": {
      "@id": "https://clearank.com/#logo"
     },
     "sameAs": [
      "https://x.com/CleaRank",
      "https://www.linkedin.com/company/clearank/",
      "https://www.youtube.com/@CleaRank",
      "https://t.me/clearank"
     ],
     "email": "info@clearank.com",
     "contactPoint": [
      {
       "@type": "ContactPoint",
       "contactType": "customer support",
       "email": "info@clearank.com",
       "url": "https://clearank.com/contact/",
       "availableLanguage": "en"
      }
     ],
     "address": {
      "@type": "PostalAddress",
      "streetAddress": "Beni Berman 2",
      "addressLocality": "Netanya",
      "addressRegion": "Center",
      "postalCode": "4249330",
      "addressCountry": "IL"
     },
     "location": {
      "@id": "https://clearank.com/#place"
     },
     "knowsAbout": [
      "stock analysis",
      "ETF analysis",
      "cryptocurrency analysis",
      "forex trading",
      "trading simulation",
      "trade journaling",
      "position sizing",
      "risk management",
      "prop firm challenges",
      "online broker regulation"
     ],
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "ethicsPolicy": "https://clearank.com/editorial-code/",
     "ownershipFundingInfo": "https://clearank.com/about-us/",
     "owns": {
      "@id": "https://clearank.com/#app"
     },
     "founder": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "WebSite",
     "@id": "https://clearank.com/#website",
     "url": "https://clearank.com",
     "name": "CleaRank",
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "inLanguage": "en-US"
    },
    {
     "@type": "ImageObject",
     "@id": "https://clearank.com/wp-content/uploads/2026/07/boston-scientific-bsx.png",
     "url": "https://clearank.com/wp-content/uploads/2026/07/boston-scientific-bsx.png",
     "width": "1280",
     "height": "720",
     "caption": "Boston Scientific Corporation (BSX) stock price analysis chart for July 2026",
     "inLanguage": "en-US"
    },
    {
     "@type": "BreadcrumbList",
     "@id": "https://clearank.com/stock/boston-scientific-bsx/#breadcrumb",
     "itemListElement": [
      {
       "@type": "ListItem",
       "position": "1",
       "item": {
        "@id": "https://clearank.com",
        "name": "Home"
       }
      },
      {
       "@type": "ListItem",
       "position": "2",
       "item": {
        "@id": "https://clearank.com/stock/boston-scientific-bsx/",
        "name": "Boston Scientific Corporation (BSX) Stock Price Analysis"
       }
      }
     ]
    },
    {
     "@type": "WebPage",
     "@id": "https://clearank.com/stock/boston-scientific-bsx/#webpage",
     "url": "https://clearank.com/stock/boston-scientific-bsx/",
     "name": "Boston Scientific (BSX) Stock Forecast & Price Target (2026)",
     "datePublished": "2026-07-03T09:18:06+00:00",
     "dateModified": "2026-09-16T05:21:39+00:00",
     "isPartOf": {
      "@id": "https://clearank.com/#website"
     },
     "primaryImageOfPage": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/boston-scientific-bsx.png"
     },
     "inLanguage": "en-US",
     "breadcrumb": {
      "@id": "https://clearank.com/stock/boston-scientific-bsx/#breadcrumb"
     },
     "reviewedBy": {
      "@id": "https://clearank.com/writer/shaundavidb/#person"
     }
    },
    {
     "@type": "Person",
     "@id": "https://clearank.com/writer/shaundavidb/#person",
     "name": "Shaun David",
     "jobTitle": "Co-Founder",
     "url": "https://clearank.com/writer/shaundavidb/",
     "image": "https://clearank.com/media/uploads/2025/01/Shaun-David-Author-Image-.jpeg",
     "sameAs": [
      "https://www.linkedin.com/in/shaun-david-697b5817a/"
     ],
     "worksFor": {
      "@id": "https://clearank.com/#organization"
     }
    },
    {
     "@type": "Article",
     "@id": "https://clearank.com/stock/boston-scientific-bsx/#richSnippet",
     "headline": "Boston Scientific (BSX) Stock Forecast & Price Target (2026)",
     "name": "Boston Scientific (BSX) Stock Forecast & Price Target (2026)",
     "description": "Boston Scientific Corp. (BSX) stock: Healthcare, Medical Devices. $63.6B market cap. AI rating, technicals, 2030 forecast and trade plans.",
     "datePublished": "2026-07-03T09:18:06+00:00",
     "dateModified": "2026-09-16T05:21:39+00:00",
     "author": {
      "@id": "https://clearank.com/#organization"
     },
     "publisher": {
      "@id": "https://clearank.com/#organization"
     },
     "publishingPrinciples": "https://clearank.com/editorial-code/",
     "about": {
      "@type": "Corporation",
      "name": "Boston Scientific Corp.",
      "identifier": [
       {
        "@type": "PropertyValue",
        "propertyID": "tickerSymbol",
        "value": "BSX"
       },
       {
        "@type": "PropertyValue",
        "propertyID": "exchange",
        "value": "NYSE"
       }
      ],
      "description": "Boston Scientific Corp. is a medical device company focused on developing, manufacturing, and marketing technologies used in interventional medical procedures worldwide. The company’s portfolio serves a broad range of clinical areas, including cardiology, peripheral interventions, endoscopy, urology",
      "tickerSymbol": "BSX",
      "sameAs": "https://www.bostonscientific.com"
     },
     "isPartOf": {
      "@id": "https://clearank.com/stock/boston-scientific-bsx/#webpage"
     },
     "image": {
      "@id": "https://clearank.com/wp-content/uploads/2026/07/boston-scientific-bsx.png"
     },
     "inLanguage": "en-US",
     "mainEntityOfPage": {
      "@id": "https://clearank.com/stock/boston-scientific-bsx/#webpage"
     }
    }
   ]
  },
  {
   "@context": "https://schema.org",
   "@type": "FAQPage",
   "mainEntity": [
    {
     "@type": "Question",
     "name": "Is Boston Scientific Corp. stock a buy right now?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Boston Scientific Corp. (BSX) is currently rated 'Sell' by our AI analysis due to heavy insider selling and bearish technicals, despite a 'Buy' consensus from Wall Street analysts. The current price is $43.87, with a median analyst target of $60.00."
     }
    },
    {
     "@type": "Question",
     "name": "What is Boston Scientific's stock price forecast for 2030?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Based on Monte Carlo simulations, Boston Scientific Corp. (BSX) has a base case forecast of $57.06 for 2030, with a downside projection of $27.82 and an upside projection of $117.04. These are statistical outcomes, not guarantees."
     }
    },
    {
     "@type": "Question",
     "name": "What are the main risks facing Boston Scientific Corp.?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "The primary risks include significant insider selling totaling over $107.9 million, a bearish technical outlook with the stock below key moving averages, and intense competition within the medical device industry."
     }
    },
    {
     "@type": "Question",
     "name": "How does Boston Scientific's valuation compare to its peers?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Boston Scientific's P/E ratio of 18.10 and P/S ratio of 3.09 are below the sector medians of 31.9 and 3.7, respectively, suggesting a potentially more attractive valuation on these metrics. Its profit margin of 17.50% also surpasses the sector median of 6.9%."
     }
    },
    {
     "@type": "Question",
     "name": "What was Boston Scientific's most recent earnings performance?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "In the quarter ending June 2026, Boston Scientific reported an EPS of $0.86, beating estimates by 3.61%. The stock price saw a slight decrease of -0.09% following this announcement."
     }
    },
    {
     "@type": "Question",
     "name": "What is the Wall Street consensus on Boston Scientific stock?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Wall Street analysts maintain a 'Buy' consensus for Boston Scientific (BSX), with 31 analysts covering the stock. There are 8 'Strong Buy' ratings, 18 'Buy' ratings, and 5 'Hold' ratings, contributing to a Wall Street score of 77 out of 100."
     }
    },
    {
     "@type": "Question",
     "name": "Are there any significant insider transactions for BSX?",
     "acceptedAnswer": {
      "@type": "Answer",
      "text": "Yes, recent insider activity for BSX indicates a heavy insider selling, with total sales amounting to $107.9 million compared to total purchases of $10 million across 94 transactions."
     }
    }
   ]
  }
 ]
}